Company Profile

Pear Therapeutics, Inc. is a commercial-stage healthcare company. The Company is engaged in developing a new class of software-based medicines that is referred to as prescription digital therapeutics (PDTs), which use software to treat diseases directly. Its products include reSET and reSET-O. The Company's reSET product is indicated for the treatment of substance use disorder (SUD) as a monotherapy. Its reSET-O product is developed for the treatment of opioid use disorder (OUD) in combination with buprenorphine. The Companyâ€™s pipeline consists of product candidates in psychiatry, neurology, and outside-of-central nervous system therapeutic areas. The Company has built a portfolio of PDT product candidates that is primarily focused on psychiatric conditions.

Employees

200

Sector

Biotechnology & Medical Research

More about the company

23/05/24	Pear Therapeutics, Inc. Went Out of Business	CI
08/05/24	Combined Liquidation Plan and Disclosure Statement Approved for Pear Therapeutics, Inc.	CI
22/03/24	Disclosure Statement and Plan Approved on Interim Basis for Pear Therapeutics, Inc.	CI
04/03/24	Combined Liquidation Plan and Disclosure Statement Filed by Pear Therapeutics, Inc.	CI
12/02/24	Third Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	CI
13/12/23	Second Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	CI
04/08/23	First Motion for Exclusivity Period Extension Approved For Pear Therapeutics, Inc.	CI
20/07/23	First Motion for Exclusivity Period Extension Filed by Pear Therapeutics, Inc.	CI
23/05/23	Motion for Asset Sale Approved for Pear Therapeutics, Inc.	CI
23/05/23	Motion for Asset Sale Approved for Pear Therapeutics, Inc.	CI
21/05/23	Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	CI
20/05/23	Asset Purchase Agreement Filed by Pear Therapeutics, Inc.	CI
19/05/23	Notice of Auction Resluts Filed by Pear Therapeutics, Inc.	CI

20/03/23	Credit Suisse Downgrades Pear Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $7	MT
20/03/23	TD Cowen Downgrades Pear Therapeutics to Market Perform From Outperform	MT
20/03/23	Chardan Downgrades Pear Therapeutics to Neutral From Buy, Citing Cash Constraints, Withdraws Price Target	MT
16/11/22	Citigroup Adjusts Price Target on Pear Therapeutics to $5 From $7, Maintains Buy Rating	MT
15/11/22	Credit Suisse Lowers Pear Therapeutics' PT to $7 From $9, Updates Model After Q3 Actuals, Management Guidance; Keeps Outperform Rating	MT

10/04/23	PEAR THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	AQ
10/04/23	PEAR THERAPEUTICS FILES FOR CHAPTER 11 AND WILL SEEK TO SELL ASSETS THROUGH SALES PROCESS	AQ
07/04/23	PEAR THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Bankruptcy or Receivership, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Costs Associated with Exit or Disposal Activities, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
07/04/23	Pear Therapeutics Files for Chapter 11 and Will Seek to Sell Assets Through Sales Process	BU
31/03/23	PEAR THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ

Manager	Title	Age	Since
Christopher Guiffre CEO	Chief Executive Officer	58	06/04/2023
Ilya Gluhovsky CTO	Chief Tech/Sci/R&D Officer	-	-
Maria Sullivan CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Corey McCann BRD	Director/Board Member	47	01/12/2021
Shiva Rajaraman BRD	Director/Board Member	52	14/06/2022

Pear Therapeutics, Inc. Stock

Stocks

PEAR

US7047231052

Biotechnology & Medical Research

Latest news: Pear Therapeutics, Inc.

Analysts' recommendations: Pear Therapeutics, Inc.

Press Releases: Pear Therapeutics, Inc.

News in other languages: Pear Therapeutics, Inc.

Managers and Directors: Pear Therapeutics, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
4/10/23 A	5AM Venture Management LLC	Sell	Company	16,544,113	11.8148%
2/15/23 A	Christopher Guiffre	Free	Chief Executive Officer	2,285,714	1.6323%
2/15/23 A	Yuri Maricich	Free	Chief Technology Officer	1,333,333	0.9522%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PEAR THERAPEUTICS, INC.	-.--%	-.--%	-	-	142
LONZA GROUP AG	+0.11%	+2.71%	+0.33%	+28.59%	46.18B
IQVIA HOLDINGS INC.	-0.71%	+1.59%	+39.81%	+27.02%	44.35B
REVOLUTION MEDICINES, INC.	-3.61%	-6.44%	+321.58%	+516.36%	42.21B
BEONE MEDICINES AG	-1.10%	+1.10%	+2.16%	+67.68%	40.19B
CELLTRION, INC.	-0.50%	-0.77%	+11.86%	+40.41%	29.83B
MEDPACE HOLDINGS, INC.	-0.79%	+3.94%	+21.66%	+123.61%	17.17B
ASCENDIS PHARMA A/S	+0.06%	-9.39%	-	-	15.7B
EUROFINS SCIENTIFIC SE	-0.57%	+8.12%	+22.15%	+38.93%	15.32B
ICON PUBLIC LIMITED COMPANY	-3.84%	-3.69%	-9.12%	-38.00%	13.09B
Average	-1.10%	+1.67%	+51.30%	+100.58%	29.34B
Weighted average by Cap.	-1.18%	+1.63%	+65.99%	+122.66%